by Garth Sundem | Dec 4, 2019 | Featured, Research
Martin McCarter, MD, and colleagues target myeloid-derived suppressor cells in melanoma In melanoma, myeloid-derived suppressor cells (MDSCs) are bad – the more MDSCs, the poorer a patient’s prognosis. That’s because when these MDSCs expand to accumulate near melanoma...
by Garth Sundem | Nov 20, 2019 | Featured, Patient Care
When you think of melanoma, you picture the sun. But there is another class of these dangerous cancers that has nothing to do with sun exposure. Mucosal melanomas arise seemingly spontaneously from mucosal tissues, accounting for about 1.3 percent of all melanomas. In...
by Garth Sundem | Nov 18, 2019 | Latest News, Philanthropy
Boston-area native, Jeremy Hugh, MD, willing to be photographed with wife wearing Yankees hat There are marathons and then there’s the Boston Marathon, when the city takes a holiday and 500,000 people line the streets ten-deep to cheer on runners from all over the...
by Garth Sundem | Apr 2, 2019 | Latest News, Research
Carol Amato, William Robinson and colleagues show that Nf-KB signaling may show which melanomas are “hot” enough to respond to immunotherapy Melanomas tend to be “hot” or “cold” – if they’re hot, immunotherapy lights melanoma tumors like beacons for...
by Garth Sundem | Nov 26, 2018 | Latest News, Research
In 1960, scientists described the “Philadelphia chromosome” that causes chronic myeloid leukemia, and in 2001 the Food and Drug Administration approved the drug imatinib to disable the action of this cancer-causing genetic change. It was the dawn of...
